IMPLICATIONS FOR PATIENT CARE: Further investigation is warranted to determine if first-line [177Lu]Lu-PSMA-617 can effectively treat metastatic prostate cancer in patients who seek to delay or avoid local treatment to the prostate and systemic therapies, including ADT. This evidence concerns the gene FOLH1 and metastatic prostate carcinoma.